MNOV

MediciNova Inc. (MNOV) | Rumor.io

MediciNova

MNOV

Attention (50-day avg)0%

Attention rank (50-day avg)#1,481

Bullish sentiment (50-day avg)67%

Price to earnings ratio-8.62

Market capitalization103.4M

Earnings per share-0.21

Dividend yield (TTM)—

Revenue (annual)409.7K

Net income (annual)-12M

Social

What share of all stock conversation is about MNOV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.02	0% +0	0% +0	0% +0

Sep 28

MediciNova's MN-001 (Tipelukast) phase 2 trial results were mixed, with significant wins on triglycerides and HDL, but liver fat reduction on the 24-week trial wasn't significant.
The company will need to conduct a retrial with more patients and a longer duration to see better results, and the next catalyst will be the MN-166 phase 3 results at the end of the year.
The stock's price tumbled on the mixed results, with some analysts questioning the clinical path forward and the company's ability to preserve confidence in the program.

Generated by AI

Sentiment

Of the messages about MNOV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	55.46% -18.41	66.18% -33.82	83.26% -5.79
Bearish	—	44.54% +18.41	33.82% +33.82	16.74% +5.79

Bullish· Sep 17

MediciNova's MN-166/Ibudilast program is a key catalyst for the company's stock price, with a Phase 2b/3 readout expected in Q4.
Roth/MKM's initiation of coverage with a $6 price target is a significant catalyst for the stock, which has already seen a 29.8% intraday surge.
The stock has the potential for a major bullish reversal, with one post predicting a +300% run in the coming days.

Bearish· Oct 31

$MNOV broke the VWAP, indicating a significant downward move in the stock.
The stock is experiencing a sell-off, with prices potentially dropping to $1.34, and investors are advised to be cautious.
Hedge funds are suspected of engaging in naked shorting, selling millions of shares to drive the price down and then abandoning the shares, which could lead to a further decline in the stock's value.

Generated by AI

Topics

Of the messages about MNOV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	91.3%	76.56%	52.2%
Analysts	—	8.7%	7.81%	12.09%
Technical Analysis	—	0%	15.63%	28.02%
Controversies	—	0%	0%	0.55%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	7.14%

Announcements· Oct 31

MediciNova's compounds have demonstrated a novel therapeutic approach for atherosclerosis in a peer-reviewed publication, with MN-002 showing enhanced cholesterol efflux.
The company's lead drug, MN-166 (ibudilast), has completed enrollment in its Phase 2b/3 ALS trial, with analysts' average target price at $7.00 and significant upside potential.
MediciNova has secured a new $30M equity facility, extending its runway for key programs, with its stock surging on the news and reaching a +70% premarket burst.

Technical Analysis· Mar 10

$MNOV has broken through a 20-day EMA at 8.50, indicating a strong bullish trend.
The stock has shown a strong bullish break, with a potential target of 15.41, and has immediate support at 7.79.
The stock's RSI is positive, and the MACD has just crossed up, indicating a potential continuation of the trend, with a key level to watch at $13.50-$14.00.

Generated by AI

Community

Of the messages about MNOV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	37.7%	43.89%	33.09%
Newcomers	—	62.3%	56.11%	66.91%

Regulars· Sep 17

MediciNova ( $MNOV ) shares surged 29.8% intraday due to a fresh Buy initiation from Roth/MKM, with a $6.00 price target.
The Buy rating is driven by enthusiasm for the company's core small-molecule pipeline asset MN-166 (ibudilast) as it advances through Phase 3 testing in amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM).
A 300% increase in one day is predicted by some, and the number of shares outstanding is significant, with 5 million shares reported.

Newcomers· Sep 28

The clinical trial results for MediciNova's MN-001 (Tipelukast) showed mixed results, with statistically significant increases in HDL-C and HDL-P, but no significant reduction in liver fat.
Investors are concerned about the implications of the trial results on the company's pipeline and are watching for clarification on the clinical path forward.
The stock price has dropped significantly, with some traders calling it a "dud" and advising others to exit their positions, while others are scaling out of their contracts and taking profits.

Generated by AI

News

H.C. Wainwright reiterates Buy on MediciNova stock, $10 target

23h agoInvesting.com

MediciNova extends office lease to 2030 and agrees to rent increases

1d agoInvesting.com

Why Is MediciNova Stock Tumbling Today? - MediciNova (NASDAQ:MNOV)

MediciNova reported Phase 2 topline trial results for tipelukast in treating NAFLD and hypertriglyceridemia.

1d agoBenzinga

Also Discussed

Investors talking about MNOV also mention

#	Name	Attention
1	Socket Mobile Inc.SCKT	0%0
2	I-Mab Sponsored ADRIMAB	0%0
3	Can-Fite BioPharma Ltd. ADRCANF	0%0
4	Siebert Financial Corp.SIEB	0%0
5	WHLM - Wilhelmina International, Inc.	——
6	NI Holdings Inc.NODK	0%0
7	TMC the metals company Inc. WarrantTMCWW	0%0
8	Apollomics Inc. - WarrantAPLMW	0%new
9	First Trust Dow Jones International Internet ETFFDNI	0%0
10	YieldMax Nasdaq 100 0DTE Covered Call Strategy ETFQDTY	0.05%new

MediciNova Inc.

Healthcare
Biotechnology

MediciNova Inc. is a biopharmaceutical company focused on developing novel small-molecule therapeutics for serious diseases with unmet medical needs. MediciNova’s current programs center on neurology, respiratory disease, and liver-related conditions, with development efforts concentrated on candidates such as MN-166 (ibudilast), MN-001 (tipelukast), and MN-221. Its pipeline targets a range of disorders including neurodegenerative, inflammatory, fibrotic, metabolic, and respiratory diseases, reflecting a portfolio built around differentiated mechanisms of action and clinical development across multiple indications. The company works through strategic alliances and clinical collaborations to advance its programs and support drug development from early research through later-stage trials. Headquartered in La Jolla, California, MediciNova Inc. occupies a specialized role in the biotechnology market by pursuing therapies for complex conditions where current treatment options remain limited.

Website

Location

4275 Executive Square

La Jolla, CA, 92037

United States

Social

What share of all stock conversation is about MNOV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.02	0% +0	0% +0	0% +0

Sep 28

MediciNova's MN-001 (Tipelukast) phase 2 trial results were mixed, with significant wins on triglycerides and HDL, but liver fat reduction on the 24-week trial wasn't significant.
The company will need to conduct a retrial with more patients and a longer duration to see better results, and the next catalyst will be the MN-166 phase 3 results at the end of the year.
The stock's price tumbled on the mixed results, with some analysts questioning the clinical path forward and the company's ability to preserve confidence in the program.

Generated by AI

Sentiment

Of the messages about MNOV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	55.46% -18.41	66.18% -33.82	83.26% -5.79
Bearish	—	44.54% +18.41	33.82% +33.82	16.74% +5.79

Bullish· Sep 17

MediciNova's MN-166/Ibudilast program is a key catalyst for the company's stock price, with a Phase 2b/3 readout expected in Q4.
Roth/MKM's initiation of coverage with a $6 price target is a significant catalyst for the stock, which has already seen a 29.8% intraday surge.
The stock has the potential for a major bullish reversal, with one post predicting a +300% run in the coming days.

Bearish· Oct 31

$MNOV broke the VWAP, indicating a significant downward move in the stock.
The stock is experiencing a sell-off, with prices potentially dropping to $1.34, and investors are advised to be cautious.
Hedge funds are suspected of engaging in naked shorting, selling millions of shares to drive the price down and then abandoning the shares, which could lead to a further decline in the stock's value.

Generated by AI

Topics

Of the messages about MNOV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	91.3%	76.56%	52.2%
Analysts	—	8.7%	7.81%	12.09%
Technical Analysis	—	0%	15.63%	28.02%
Controversies	—	0%	0%	0.55%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	7.14%

Announcements· Oct 31

MediciNova's compounds have demonstrated a novel therapeutic approach for atherosclerosis in a peer-reviewed publication, with MN-002 showing enhanced cholesterol efflux.
The company's lead drug, MN-166 (ibudilast), has completed enrollment in its Phase 2b/3 ALS trial, with analysts' average target price at $7.00 and significant upside potential.
MediciNova has secured a new $30M equity facility, extending its runway for key programs, with its stock surging on the news and reaching a +70% premarket burst.

Technical Analysis· Mar 10

$MNOV has broken through a 20-day EMA at 8.50, indicating a strong bullish trend.
The stock has shown a strong bullish break, with a potential target of 15.41, and has immediate support at 7.79.
The stock's RSI is positive, and the MACD has just crossed up, indicating a potential continuation of the trend, with a key level to watch at $13.50-$14.00.

Generated by AI

Community

Of the messages about MNOV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	37.7%	43.89%	33.09%
Newcomers	—	62.3%	56.11%	66.91%

Regulars· Sep 17

MediciNova ( $MNOV ) shares surged 29.8% intraday due to a fresh Buy initiation from Roth/MKM, with a $6.00 price target.
The Buy rating is driven by enthusiasm for the company's core small-molecule pipeline asset MN-166 (ibudilast) as it advances through Phase 3 testing in amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM).
A 300% increase in one day is predicted by some, and the number of shares outstanding is significant, with 5 million shares reported.

Newcomers· Sep 28

The clinical trial results for MediciNova's MN-001 (Tipelukast) showed mixed results, with statistically significant increases in HDL-C and HDL-P, but no significant reduction in liver fat.
Investors are concerned about the implications of the trial results on the company's pipeline and are watching for clarification on the clinical path forward.
The stock price has dropped significantly, with some traders calling it a "dud" and advising others to exit their positions, while others are scaling out of their contracts and taking profits.

Generated by AI

MediciNova

Social

Sep 28

Bullish· Sep 17

Bearish· Oct 31

Announcements· Oct 31

Technical Analysis· Mar 10

Regulars· Sep 17

Newcomers· Sep 28

H.C. Wainwright reiterates Buy on MediciNova stock, $10 target

MediciNova extends office lease to 2030 and agrees to rent increases

Why Is MediciNova Stock Tumbling Today? - MediciNova (NASDAQ:MNOV)

MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints

Why is MediciNova stock sliding today?

MediciNova stock tumbles on mixed Phase 2 NAFLD trial data

Also Discussed

MediciNova Inc.

Company Information

Location

H.C. Wainwright reiterates Buy on MediciNova stock, $10 target

MediciNova extends office lease to 2030 and agrees to rent increases

Why Is MediciNova Stock Tumbling Today? - MediciNova (NASDAQ:MNOV)

MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints

Why is MediciNova stock sliding today?

MediciNova stock tumbles on mixed Phase 2 NAFLD trial data

Also Discussed

Social

Sep 28

Bullish· Sep 17

Bearish· Oct 31

Announcements· Oct 31

Technical Analysis· Mar 10

Regulars· Sep 17

Newcomers· Sep 28